Similar to our findings in the mouse BCC cell line, SMO plus AP-1 inhibitors have an additive effect in reducing Gli1 expression, while AP-1 plus ALK5 inhibitors do not (Supplementary Fig. 5i). This evidence concerns the gene JUND and skin basal cell carcinoma.